Active, not recruitingPhase 3NCT06079359

Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP

Studying Hypophosphatasia

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Alexion Pharmaceuticals, Inc.
Intervention: ALXN1850(drug)
Enrollment: 30 enrolled
Eligibility: 2-11 years · All sexes
Timeline: 2024 – 2028

Study locations (30)

Research Site, Baltimore, Maryland, United States
Research Site, Kansas City, Missouri, United States
Research Site, Durham, North Carolina, United States
Research Site, Nedlands, Australia
Research Site, Parkville, Australia
Research Site, Brussels, Belgium
Research Site, Brasília, Brazil
Research Site, Porto Alegre, Brazil
Research Site, Recife, Brazil
Research Site, Salvador, Brazil
Research Site, São Paulo, Brazil
Research Site, Calgary, Alberta, Canada
Research Site, Winnepeg, Manitoba, Canada
Research Site, Beijing, China
Research Site, Guangzhou, China
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06079359 on ClinicalTrials.gov

Other trials for Hypophosphatasia

Additional recruiting or active studies for the same condition.

See all trials for Hypophosphatasia →

← Back to all trials